(Q37857854)

24 August 2017

1 reference

title

Influenza pharmacotherapy: present situation, strategies and hopes (English)

1 reference

24 August 2017

0 references

Paolo Preziosi

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

26 March 2011

1 reference

Expert Opinion on Pharmacotherapy

24 August 2017

published in

1 reference

24 August 2017

volume

12

1 reference

24 August 2017

issue

10

1 reference

24 August 2017

page(s)

1523-1549

1 reference

How severe will the flu outbreak be?

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Clinical practice. Prevention and treatment of seasonal influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Current and future antiviral therapy of severe seasonal and avian influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Mutations of neuraminidase implicated in neuraminidase inhibitors resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

The persistent legacy of the 1918 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

A/H1N1 influenza: questions and answers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Emerging antiviral targets for influenza A virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Complications of viral influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Human metapneumovirus infections in adults: another piece of the puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Drugs in development for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Medical management of influenza infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Strategies of development of antiviral agents directed against influenza virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Avian influenza virus (H5N1): a threat to human health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Antivirals for influenza in healthy adults: systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Developing new antiviral agents for influenza treatment: what does the future hold?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Plaque inhibition assay for drug susceptibility testing of influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Structure and mechanism of the M2 proton channel of influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Antiviral resistance in influenza viruses--implications for management and pandemic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Antivirals and influenza: frequency of resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Mechanism of drug inhibition and drug resistance of influenza A M2 channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Distribution of amantadine-resistant H5N1 avian influenza variants in Asia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

The evolution of influenza resistance and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Cardiotoxicity after massive amantadine overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Oseltamivir in the management of influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Clinical benefits with oseltamivir in treating influenza in adult populations : results of a pooled and subgroup analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

What can we learn from observational studies of oseltamivir to treat influenza in healthy adults?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Neuraminidase inhibitors—the story behind the Cochrane review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Critical care services and 2009 H1N1 influenza in Australia and New Zealand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Recovery of drug-resistant influenza virus from immunocompromised patients: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Oseltamivir resistance during treatment of influenza A (H5N1) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Global transmission of oseltamivir-resistant influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

First cases of spread of oseltamivir resistant swine flu between patients are reported in Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Structure of the catalytic and antigenic sites in influenza virus neuraminidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Fatal oseltamivir-resistant influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Possible harms of oseltamivir--a call for urgent action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

A/H1N1 pandemic. Oseltamivir's adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Health outcomes among patients receiving oseltamivir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

The truth about Tamiflu? Zanamivir should be inhaled, not nebulised

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

H1N1 pneumonitis treated with intravenous zanamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Zanamivir: a review of clinical safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

21 January 2018

Flu's unexpected bonus

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Losing the opportunity to study influenza drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Antibody recognition of a highly conserved influenza virus epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab')2 fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Molecular strategies to inhibit the replication of RNA viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Oral ribavirin treatment of influenza A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Original research: Intravenous ribavirin--review of the FDA's Emergency Investigational New Drug Database (1997-2008) and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Use of ribavirin to treat influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

In vitro and in vivo influenza virus-inhibitory effects of viramidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Treating HCV with ribavirin analogues and ribavirin-like molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

The structural basis for an essential subunit interaction in influenza virus RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

In vitro and in vivo activities of anti-influenza virus compound T-705.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Identification of influenza A nucleoprotein as an antiviral target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Discovery of novel antiviral agents directed against the influenza A virus nucleoprotein using photo-cross-linked chemical arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Epidemiology and pathogenesis of influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Influenza A strain-dependent pathogenesis in fatal H1N1 and H5N1 subtype infections of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications for treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Insights into inflammation and influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Modulation of cytokine production by 7-hydroxycoumarin in vitro and its efficacy against influenza infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

2009 H1N1 virus transmission and outbreaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

1918 Spanish influenza: the secrets remain elusive

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Clinical characteristics of paediatric H1N1 admissions in Birmingham, UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Swine-origin influenza virus H1N1, seasonal influenza virus, and critical illness in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Effects of oseltamivir on influenza-related complications in children with chronic medical conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Tamiflu and neuropsychiatric disturbance in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Oseltamivir and delirious behavior in children with influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Twenty years and counting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Role of combination antiviral therapy in pandemic influenza and stockpiling implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Acute encephalopathy associated with influenza and other viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

The effect of antipyretic therapy upon outcomes in critically ill patients: a randomized, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

A/H1N1 flu. Time for case-control studies of NSAIDs and oseltamivir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

H1N1 2009 influenza virus infection during pregnancy in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Pandemic H1N1 infection in pregnant women in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Why don't we have all the evidence on oseltamivir?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Tamiflu side effects come under scrutiny

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Antiviral drugs: distinguish treatment from prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

Portrait of a year-old pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

WHO is accused of "crying wolf" over swine flu pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.566557

10.1517/14656566.2011.566557

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference